| 2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
| ONCOTARGET |
| 2020 | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
| LUNG CANCER |
| 2022 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2020 | First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
| EUROPEAN JOURNAL OF CANCER |
| 2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | JOURNAL OF CLINICAL ONCOLOGY |
| 2009 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | LANCET ONCOLOGY |
| 2021 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC | JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2010 | Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
| CANCER |
| 2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2022 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
| CURRENT ONCOLOGY |
| 2016 | Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
| ONCOTARGET |
| 2013 | Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation | MOLECULAR CANCER THERAPEUTICS |
| 2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| SCIENTIFIC REPORTS |
| 2012 | High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma
| CLINICAL CANCER RESEARCH |
| 2009 | High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
| CLINICAL CANCER RESEARCH |
| 2016 | Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation. | TECHNOLOGY IN CANCER RESEARCH & TREATMENT |
| 2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |
| 2019 | Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance | IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS |
| 2014 | Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
| GENOME MEDICINE |
| 2019 | Identification of TRE-130 as Reversible Inhibitor of Pan-EGFR Mutants while Sparing EGFR Wild-Type Activity | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
| 2018 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions | LUNG CANCER |
| 2014 | Immunotherapy in the treatment of non-small cell lung cancer | LUNG CANCER |
| 2017 | Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042) | LUNG CANCER |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | LUNG CANCER |
| 2010 | Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2018 | Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
| CANCER IMMUNOLOGY RESEARCH |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
| 2016 | Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
| 2021 | Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
| 2019 | Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
| Cancer Research and Treatment |
| 2019 | Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection
| Cancer Research and Treatment |
| 2021 | KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
| FUTURE ONCOLOGY |
| 2015 | Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
| PLOS ONE |
| 2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Lazertinib: on the Way to Its Throne
| YONSEI MEDICAL JOURNAL |
| 2019 | LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study | ANNALS OF ONCOLOGY |
| 2022 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
| JTO Clinical and Research Reports |
| 2020 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Lung cancer in never smokers: change of a mindset in the molecular era. | LUNG CANCER |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2023 | Management of HER2 alterations in non-small cell lung cancer - The past, present, and future | LUNG CANCER |
| 2023 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
| LUNG CANCER |
| 2022 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer | FUTURE ONCOLOGY |
| 2018 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors | ANNALS OF ONCOLOGY |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
| PLOS ONE |
| 2019 | Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2011 | Multiple target loci assembly sequencing (mTAS). | ANALYTICAL BIOCHEMISTRY |
